Expert Opinion on Pharmacotherapy

Papers
(The H4-Index of Expert Opinion on Pharmacotherapy is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Oral anticoagulation therapy in the setting of liver disease69
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook50
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond48
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges44
Current treatment options for Mycobacterium marinum cutaneous infections41
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis38
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease38
The pharmacological treatment and management of hyperhidrosis35
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan31
Pharmacotherapy developments in autophagy inhibitors for bladder cancer29
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy28
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis27
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives26
Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management26
How have gamma-secretase inhibitors changed the treatment landscape for desmoid tumors?26
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten25
Pivmecillinam: past, present, and future24
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy24
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma23
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants23
Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective21
Selecting optimal therapy in systemic mastocytosis: current state and future directions21
Pharmacologic management of ET: established therapies and emerging agents21
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?21
0.11779594421387